Opinion

Video

Assessing HER2 Status Across Tumor Types

Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.

  • How do HER2 mutations differ from HER2 overexpression and gene amplification in terms of their impact on cancer?
    • How can this differ among cancer types?
  • What are the incidences of HER2 overexpression across solid tumors? HER2 mutations?
  • What is your current practice for testing for HER2?What testing methodologies are used? How do they differ and what can you learn from each?
    • What is the difference between HER2 amplification and IHC score? What are best practices to ensure patients with HER2 amplification aren’t missed?
    • Does this vary among solid tumors?
    • How have levels of HER2 expression changed? What percent of patients typically have HER2-low expression?
  • Is what is known about HER2 expression/mutations from research in breast and other cancer types applicable to other solid tumor types? Are there unique aspects to consider?
  • How might current understanding of HER2 expression and HER2 mutations in other solid tumors contribute to the development of future targeted therapies or personalized treatment approaches?

Related Videos
Video 4 - 2 KOLs are featured in, "Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC"
Video 2 - 2 KOLs are featured in, "Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway"
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
4 KOLs are featured in this series
2 KOLs are featured in this series
2 KOLs are featured in this series
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
Related Content